A comparison of three measures of upper limb function in Friedreich ataxia

• Published in: Journal of neurology Vol. 257; no. 4; pp. 518 - 523
• Main Authors: Corben, L. A., Tai, G., Wilson, C., Collins, V., Churchyard, A. J., Delatycki, M. B.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.04.2010; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Ataxia; Biological and medical sciences; Cardiomyopathy; Clinical trials; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Disability Evaluation; Female; Friedreich Ataxia - genetics; Friedreich Ataxia - pathology; Friedreich Ataxia - physiopathology; Humans; Male; Medical sciences; Medicine; Medicine & Public Health; Membrane Glycoproteins - genetics; Middle Aged; Mutation; Neurologic Examination - methods; Neurology; Neuroradiology; Neurosciences; Original Communication; Outcome Assessment (Health Care); Psychomotor Performance; Severity of Illness Index; Upper Extremity - physiopathology; Young Adult; Australia; Clinical endpoint; Outcome measures; Functional composite; Nervous system diseases; Prognosis; Genetic disease; Cerebral disorder; Central nervous system disease; Degenerative disease; Friedreich ataxia; Upper limb; Spinal cord disease; Comparative study
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-009-5352-7

Friedreich Ataxia (FRDA) is the commonest inherited ataxia. Clinical trials of pharmaceuticals are increasingly being conducted in this condition. This requires the most accurate outcome measures to enable trials to be conducted with a minimum number of subjects in the shortest time frame and to minimize the risk of false negative results. Upper limb function is a major area of morbidity in FRDA. We therefore have compared the performance of three tests of upper limb function in FRDA: the Nine Hole Peg Test (9HPT), Box and Blocks Test (BBT) and Jebsen Taylor Hand Function Test (JTHFT). This study was undertaken to ascertain the best test for inclusion in a Friedreich Ataxia Functional Composite (FAFC) test for use in clinical studies and therapeutic trials. The three tests were administered to the dominant and non-dominant upper limbs of 38 individuals with genetically proven FRDA on two occasions, 12 months apart. The results of testing were correlated with the following disease parameters; age at disease onset, disease duration and score for the Friedreich Ataxia Rating Scale (FARS). The responsiveness to change of each test was assessed by measuring the effect size and calculations of the number of subjects required for similarly powered therapeutic trials. Results for all tests correlated significantly with disease duration and FARS score. The only test scores that changed significantly over 12 months were those for the non-dominant 9HPT and BBT. Scores for these two tests also had the largest effect sizes and required the fewest subjects for similarly powered therapeutic trials. We conclude, therefore, that the non-dominant 9HPT and BBT are the best tests for inclusion in a FAFC. Since the 9HPT has already been suggested for inclusion in a FAFC, we recommend that this test is used but that it is the non-dominant limb that is tested.